• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Risk of major adverse cardiovascular events varies with dynamic metabolic syndrome status

byThomas SuandDeepti Shroff Karhade
December 4, 2019
in Cardiology, Chronic Disease, Endocrinology, Gastroenterology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this retrospective study involving South Koreans with no history of major adverse cardiovascular events (MACE), persons who developed metabolic syndrome (MetS) within the three-year inclusion period were at significantly increased risk of MACE versus those who remained free of the condition. Persons who had MetS at the beginning of the study and recovered before the end faced a significantly lower MACE risk compared to those who did not.

2. While MetS-developed and MetS chronic patients had similar risks for MACE, patients in the MetS-recovery group retained a higher risk than patients in the MetS-free group, underscoring the immediacy and persistence of the condition’s effects on the cardiovascular system.

Evidence Rating Level: 2 (Good)

Study Rundown: While it is well known that patients with metabolic syndrome (MetS) face an increased risk for major adverse cardiovascular events (MACE), it is unclear whether development of or recovery from MetS affects the incidence rate of MACE. Given the increasing medical burden of these concomitant illnesses, it is essential to better characterize this association. This study relied on health screening data from the National Health Insurance Service of Korea and found that MACE risk varied strongly with dynamic MetS status during the three-year inclusion period. The MetS-chronic group faced the highest risk, followed by the MetS-developed, MetS-recovery, and MetS-free groups, respectively. The components of MetS were analyzed, and hypertension was found to have the strongest association with MACE risk. These results support preventative public health policies and highlight the clinical importance of a MetS history. A major strength of this study was that it utilized comprehensive health information from an extremely large population. However, this study’s retrospective nature made it difficult to detecting confounding factors, and the short follow-up and homogenous cohort composition affected generalizability of findings.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: The Global Epidemic of the Metabolic Syndrome

RELATED REPORTS

Energy-reduced Mediterranean diet with increased physical activity may significantly reduce risk of type 2 diabetes

#VisualAbstract: Once-weekly Semaglutide Reduces Body Weight in People with Obesity

Tirzepatide leads to greater weight loss than semaglutide among adults with obesity

In-Depth [retrospective cohort]: In this nationwide population-based study, South Korean adults with no history of MACE were divided into four categories according to MetS status over a 3-year timeframe. Over 9.5 million persons met the inclusion criteria of identifiable MetS status at 3 or more health examinations during the inclusion period. Some exclusion criteria were transient change in MetS status, change in MetS status at the third examination, and underlying kidney function impairment. Persons were considered to have MetS if they displayed 3 or more of the following components: increased waist circumference (≥90 cm for Asian men and ≥80 cm for Asian women); elevated triglyceride level (≥50 mg/dL); reduced high-density lipoprotein cholesterol level (<40 mg/dL for men and 50 mg/dL for women); elevated blood pressure (systolic ≥130 mm Hg and/or diastolic ≥80 mm Hg); and elevated fasting glucose level (≥100 mg/dL). Of these components, development of and recovery from hypertension had the greatest impacts on MACE risk. MACE occurred most frequently in the MetS-chronic group (8.52 events per 1000 person-years) and MetS-developed group (6.05 events per 1000 person-years). The MetS-recovery group (4.55 events per 1000 person-years) and MetS-free group (1.92 events per 1000 person-years) faced the lowest risk of MACE.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiac riskhypertensionmetabolic syndromemortalityobesity
Previous Post

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

Next Post

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RelatedReports

Mediterranean diet may reduce age-related neurocognitive decline
Endocrinology

Energy-reduced Mediterranean diet with increased physical activity may significantly reduce risk of type 2 diabetes

August 28, 2025
#VisualAbstract: Once-weekly Semaglutide Reduces Body Weight in People with Obesity
StudyGraphics

#VisualAbstract: Once-weekly Semaglutide Reduces Body Weight in People with Obesity

August 27, 2025
Parental conceptions of weight are becoming increasingly inaccurate
Cardiology

Tirzepatide leads to greater weight loss than semaglutide among adults with obesity

August 26, 2025
Tramadol use linked with increased risk of hypoglycemia hospitalizations
Pharma

Lilly Strikes $1.3 Billion GPCR Drug Discovery Pact with Superluminal

August 20, 2025
Next Post
#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Adalimumab aids in control of noninfectious uveitis

Optic nerve ultrasonography can be used to detect elevated intracranial pressure

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Utility of long-term routine laboratory toxicity monitoring of immunomodulatory drugs in rheumatoid arthritis
  • Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer
  • The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.